AI Summary
About
Viz.ai is a San Francisco– and Tel Aviv–based AI-powered care-coordination company for time-sensitive disease, founded in 2016 by Dr. Chris Mansi (a neurosurgeon) and David Golan. Its platform detects suspected disease on medical imaging in real time, then coordinates the care team — pinging the right on-call specialist’s phone within seconds, sharing images, and orchestrating transfer and treatment. The flagship module, Viz LVO, flags suspected large-vessel-occlusion strokes on CT angiography and parallel-alerts the stroke team. The platform now spans more than 50 FDA-cleared algorithms organized into disease suites — Viz Neuro, Viz Cardio, Viz Vascular, Viz Pulmonary and more — covering stroke, aneurysm, hemorrhage, hypertrophic cardiomyopathy, cardiac amyloidosis, aortic disease, and pulmonary embolism, analyzing CT scans, EKGs and echocardiograms.
Viz.ai reached unicorn status with a $100M Series D in April 2022 led by Tiger Global and Insight Partners at a $1.2B valuation, after crossing 1,000 hospitals on the platform. Third-party trackers report revenue of roughly $40M in 2023 (about double the prior year) on a path toward a stated ~$100M ARR target, with ~$250M+ raised in total. The company has since extended into a Life Sciences business, partnering with pharma to find and route eligible patients.
For the most current information, visit Viz.ai. Note: there is no public pricing page — every CTA is “Request a demo” or “Speak to an expert.”
Pricing summary : How Viz.ai’s pricing model works
Viz.ai is fully sales-led: there is no published price list, no self-serve signup, and no /pricing page — every button on the site says “Request a demo” or “Speak to an expert.” Pricing is a quoted per-facility (per-hospital) annual subscription, sold modularly by disease suite (Viz Neuro, Cardio, Vascular, Pulmonary and more). Total contract value scales with how many of the 50+ FDA-cleared algorithms a hospital licenses and the size of the population it serves, so a single-pathway primary stroke center and a multi-suite comprehensive health system pay very differently.
The distinctive mechanic is reimbursement. Viz LVO was the first AI software ever granted a Medicare New Technology Add-on Payment (NTAP) — up to $1,040 per eligible use in suspected-stroke patients. NTAP pays a hospital 65% of the lesser of the technology’s cost or the amount a case exceeds the standard MS-DRG, on top of the DRG. For a hospital seeing enough Medicare stroke patients, that per-use payment effectively offsets the annual subscription, turning a software line item into something closer to cost-neutral. Third-party analyses of CMS filings have cited roughly $25,000/year as an indicative subscription example for the stroke module (varying by primary vs comprehensive stroke center) — treat that as third-party-reported, not an official price.
What makes this different: unlike the token- and seat-metered AI tools elsewhere in this corpus, Viz.ai sells into clinical-workflow and revenue-cycle budgets and pairs its subscription with a public reimbursement pathway. Hospitals don’t just buy software; they buy a coordinated stroke (or cardiac, or PE) pathway whose Medicare NTAP and downstream procedure volume (more thrombectomies at comprehensive centers) form an explicit ROI case.
Pricing by product
| Offering | Reported price | Included | Key mechanics |
|---|---|---|---|
| Viz Neuro Suite (incl. Viz LVO) | Quoted | Stroke/LVO triage, aneurysm, ICH; mobile care-team alerting | Per-facility annual subscription; Viz LVO eligible for Medicare NTAP (up to $1,040/use) |
| Viz Cardio / Vascular / Pulmonary | Quoted | HCM, amyloidosis, aortic, PE pathways across 50+ algorithms | Licensed modularly; scaled by algorithms + population |
| Viz.ai One platform (health system) | Contact sales | Multi-suite deployment, PACS/EHR integration, patient finding | Annual enterprise contract; HIPAA/BAA; outcome/ROI framing |
Sales motions across products: sales-led only — demo / “speak to an expert” → scoping → custom per-facility quote → annual contract. No free tier, no monthly option, no self-serve. The same hospital can attach one suite or several, so contract value depends on suite mix, algorithm count, and population served. Figures shown are from Viz.ai’s own pages and CMS filings, not a posted rate card.
Hidden costs : What Viz.ai users actually pay
Because pricing is quoted and modular, the real cost is shaped by which disease suites you attach, how many algorithms you light up, and the population you serve — not a published rate card. The biggest cost-shaping factors: each suite (Neuro, Cardio, Vascular, Pulmonary) is a separate line, so multi-pathway deployments multiply contract value; integration touches PACS, EHR and on-call clinician mobile devices; and the value (and the NTAP offset) only materializes if the hospital actually sees enough eligible patients.
| Line item | Annual cost |
|---|---|
| Disease suite subscription (per facility) | Quoted — scaled by suite mix, algorithms, and population served |
| Additional suites / algorithms | Quoted — scales with suite mix and population |
| PACS / EHR integration + rollout | Typically scoped into the contract |
| Less: Medicare NTAP for Viz LVO | Up to $1,040 per eligible Medicare stroke use (offset) |
| Estimated net total | Custom quote — offset by NTAP and downstream volume |
Outside the quote itself, the things to budget for are the annual commitment (this is enterprise clinical software, not month-to-month), integration and change-management effort, and the eligibility math: as one widely-cited analysis put it, a primary stroke center that doesn’t generate the downstream surgical revenue may rely on the NTAP to break even, while a comprehensive stroke center that bills well for thrombectomy may profit from increased volume but see less NTAP — so the same subscription nets out very differently by facility type. The opacity of comparison (no posted price) means apples-to-apples evaluation requires a sales process.
Want to estimate your own Viz.ai bill? Use the Viz.ai pricing calculator to model your costs based on suites, algorithms, and patient volume.
Pricing evolution : Viz.ai pricing history and changes
Cadence
| Period | Price changes | Product / SKU additions | Notes |
|---|---|---|---|
| 2016 | — | Company founded | Viz LVO / ContaCT stroke triage |
| 2020 H2 | No public list | First AI Medicare NTAP (up to $1,040/use) | Reimbursement pathway established |
| 2021 | No public list | NTAP renewed through FY2022 | Reviewed annually; 3-year expiry |
| 2022 | No public list | $100M Series D ($1.2B valuation) | Crossed 1,000 hospitals |
| 2026 | No public list | 50+ FDA-cleared algorithms across disease suites | No /pricing page; per-facility, modular |
Tracked range: 2016–present. Viz.ai has never published a public price list, so there are no Wayback price snapshots to chart — the evolution here is product, reimbursement, and go-to-market (NTAP, funding, suite launches), not posted rate cards.
Notable changes
- 2020-09 — Viz LVO becomes the first AI software granted a Medicare NTAP, up to $1,040 per use in suspected-stroke patients — establishing a reimbursement offset to the subscription.
- 2021-08 — CMS renews the Viz LVO NTAP through FY2022 (up to $1,040 per eligible patient). NTAP is reviewed annually and expires after three years.
- 2022-04 — $100M Series D led by Tiger Global and Insight Partners at a $1.2B valuation; platform crosses 1,000 hospitals. Pricing stays sales-led.
- 2026-06 — Live site has no pricing page; all CTAs are “Request a demo.” The platform spans 50+ FDA-cleared algorithms in disease suites, quoted per facility and scaled by algorithms and population.
What’s unique : Viz.ai’s distinctive pricing mechanics
1. Reimbursement-as-offset (the NTAP play). Viz.ai pioneered the first AI Medicare NTAP — up to $1,040 per eligible stroke use. Rather than asking a hospital to absorb the full subscription, the NTAP pays back a per-use add-on on top of the DRG, so the software can net out close to cost-neutral for Medicare stroke volume. No pure-software AI vendor in this corpus has an equivalent reimbursement lever baked into its pricing.
2. Per-facility, modular by disease suite. Pricing is quoted per hospital, scaled by how many of 50+ FDA-cleared algorithms are licensed and the population served, and organized into suites (Neuro, Cardio, Vascular, Pulmonary). Two hospitals of similar size can pay very differently depending on which pathways they run — a packaging structure that drives land-and-expand across disease areas.
3. Outcome/ROI framing on downstream volume. Beyond NTAP, Viz.ai pitches clinical-and-financial outcomes: cutting time-to-specialist from ~58.7 to ~7.3 minutes and reportedly lifting thrombectomy/surgery volume 50–60% at large hubs. The buying conversation centers on faster door-to-treatment and more reimbursable downstream procedures, not a per-seat fee.
Strengths & weaknesses
| Strengths | Weaknesses |
|---|---|
| NTAP reimbursement offsets the subscription for Medicare stroke volume | No public pricing at all — no /pricing page, everything quoted |
| Modular disease suites enable land-and-expand across pathways | Suite-by-suite pricing is opaque until you get a quote |
| Value maps to real budgets (door-to-treatment time, downstream procedures) | NTAP is time-limited (annual review, 3-year expiry) — offset can lapse |
| Deep workflow integration (PACS/EHR/mobile) and strong clinical proof | ROI/NTAP economics differ sharply by facility type (primary vs comprehensive) |
| Strong adoption + funding (1,000+ hospitals, $1.2B valuation) | Enterprise-only: no free tier, no self-serve, no monthly option |
Billing UX : Viz.ai billing controls and transparency
- Billing controls — Enterprise contract-based: annual commitment, no self-serve plan changes, no monthly billing. Adding a disease suite or more algorithms goes through the account team and a contract amendment, not an in-app toggle. The NTAP add-on is billed by the hospital to Medicare per eligible case, separate from the Viz.ai subscription invoice.
- Usage visibility — Viz.ai’s product surfaces operational and clinical dashboards (time-to-treatment, alerting, care-team coordination) and clinical-validation data, but there is no public cost calculator or posted rate card for the software itself. Reimbursement guidance is provided via a sales-gated NTAP resource.
- Payment options — Invoiced annual enterprise contracts via direct sales, alongside a HIPAA/security review and BAA. Deployment integrates with existing PACS and EHR and pushes alerts to on-call clinician mobile devices.
Strategic wins : Why Viz.ai’s pricing decisions worked
1. Engineering a reimbursement pathway
Securing the first-ever AI Medicare NTAP ($1,040/use) was a pricing masterstroke: it lets Viz.ai sell into hospitals that would otherwise balk at a new software line, because the cost is partially reimbursed per eligible case. Tying price to an established Medicare mechanism converts a budget objection into a near-cost-neutral case. See outcome-based pricing trends.
2. Modular suites for land-and-expand
Starting with stroke (Viz Neuro) and expanding into Cardio, Vascular, and Pulmonary creates a natural expansion path within the same hospital — growing contract value across new pathways without a fresh procurement each time. See how AI companies structure pricing.
3. Selling the downstream outcome
By framing value on door-to-treatment time and downstream procedure volume (more thrombectomies at comprehensive centers), Viz.ai sidesteps “what does software cost?” and makes the pitch about faster care and revenue. See choosing the right usage metric.
Areas to improve : Gaps in Viz.ai’s pricing approach
1. Zero list-price transparency
No /pricing page and no published rate card force every buyer into a demo just to learn rough cost. Even a posted “starting at” or a public methodology would reduce friction for smaller primary stroke centers and shorten evaluation. See bill shock and cost unpredictability.
2. NTAP-dependent economics are fragile
NTAP is reviewed annually and expires after three years; the offset can shrink or lapse. A hospital that underwrote its purchase on the reimbursement could face a different cost picture if the add-on changes — a risk that should be modeled, not assumed.
3. Eligibility math penalizes smaller centers
As widely-cited analysis notes, a primary stroke center must guess whether it will see enough eligible patients to recoup the subscription, while comprehensive centers profit from downstream volume. A clearer, volume-based or capped entry SKU would lower the bar for smaller facilities.
Key takeaways
- Viz.ai publishes nothing — pricing is fully sales-led. There is no /pricing page and every CTA is “Request a demo”; expect a quoted per-facility annual subscription, modular by disease suite.
- Per-facility, scaled by algorithms and population. Contract value depends on which of the 50+ FDA-cleared algorithms and disease suites a hospital licenses and the size of the population it serves.
- NTAP is the distinctive lever. Viz LVO was the first AI with a Medicare NTAP (up to $1,040 per use) — a per-use reimbursement that offsets the subscription for Medicare stroke volume.
- Outcome framing, not a seat fee. The pitch centers on door-to-treatment time (~58.7→7.3 min) and downstream procedure volume (+50–60% at hubs), not per-user licensing.
- Enterprise posture underwrites the model. 1,000+ hospitals and a $1.2B valuation (Series D, Tiger Global/Insight) on an annual-contract, HIPAA/EHR-integrated motion.
UBP implications
- A reimbursement pathway can be a pricing strategy. Viz.ai’s NTAP shows that aligning a product with an existing payer mechanism (Medicare add-on) can offset list price and dissolve budget objections — a uniquely healthcare lever, but a template for tying price to a recognized value transfer. See usage-based pricing strategy.
- Modular value metrics let one vendor span pathways and budgets — stroke, cardiac, vascular, pulmonary — so the same hospital can be monetized from multiple clinical lines. See choosing the right usage metric.
- Full opacity is a deliberate enterprise choice, trading shorter sales cycles for negotiating leverage and deep integration moats; it works at high ACV in regulated healthcare but blocks the bottom-up adoption that powers PLG competitors.
Sources
- Viz.ai official website (live capture, accessed 2026-06-10)
- Viz.ai — Granted Medicare New Technology Add-on Payment (NTAP) (live capture, accessed 2026-06-10) — “$1,040 per use”
- Viz.ai — NTAP renewal for stroke AI software from CMS (accessed 2026-06-10)
- PMC — “New Technology Add-On Payment (NTAP) for Viz LVO: a win for stroke care” (CMS mechanic second-source; 65% of lesser of cost or DRG excess, capped $1,040; FY2021) (accessed 2026-06-10)
- Out-Of-Pocket — Viz.ai and why workflow > tech (third-party; ~$25K/yr indicative, primary vs comprehensive center economics, 58.7→7.3 min, +50–60% surgery volume) (accessed 2026-06-10)
- Viz.ai — Raises $100M Series D at $1.2B valuation (accessed 2026-06-10)
- Sacra — Viz.ai revenue, valuation & funding (third-party; subscription scaled by algorithms + population, ~$40M 2023 revenue) (accessed 2026-06-10)
Bottom line
Viz.ai is a San Francisco/Tel Aviv care-coordination company ($1.2B valuation, 1,000+ hospitals, 50+ FDA-cleared algorithms) that detects time-sensitive disease — stroke, aneurysm, PE, cardiac — and coordinates the care team in seconds. Its pricing is fully sales-led with no public list: a quoted per-facility annual subscription, modular by disease suite (Neuro, Cardio, Vascular, Pulmonary) and scaled by algorithms licensed and population served. The distinctive mechanic is reimbursement — Viz LVO was the first AI software granted a Medicare NTAP (up to $1,040 per use), a per-case add-on that offsets the subscription — paired with an outcome/ROI pitch on faster door-to-treatment time and downstream procedure volume. Browse the pricing blueprint for more fully-researched company profiles.
Want to compare Viz.ai against other healthcare and enterprise AI companies? Browse the pricing blueprint.
Pricing timeline : Major events on a vertical axis
Each milestone below corresponds to a public pricing change, product launch, or material adjustment. Major events use a filled marker; minor adjustments use a faded one.
Sales-only per-facility model, modular disease suites, 50+ FDA-cleared algorithms
Live capture: viz.ai has no pricing page; every CTA is 'Request a demo' / 'Speak to an expert'. The platform spans 50+ FDA-cleared algorithms organized into disease suites (Neuro, Cardio, Vascular, Pulmonary and more), quoted per facility and scaled by algorithms licensed and population served. Viz LVO's NTAP remains the distinctive reimbursement offset.
$100M Series D at a $1.2B valuation (unicorn)
Viz.ai raised a $100M Series D led by Tiger Global and Insight Partners at a $1.2B valuation, surpassing 1,000 hospitals on the platform. Pricing stayed sales-led — quoted per-facility annual subscriptions, modular by disease suite, no public list.
CMS renews Viz LVO NTAP through FY2022
CMS renewed the Viz LVO NTAP, keeping eligible reimbursement at up to $1,040 per eligible patient through fiscal year 2022. NTAP designations are reviewed annually and expire after three years, so the reimbursement offset is time-limited and subject to renewal.
Viz LVO becomes first AI with a Medicare NTAP (up to $1,040/use)
CMS selected Viz LVO (formerly Viz ContaCT) as the first AI software ever to receive a Medicare New Technology Add-on Payment — up to $1,040 per use in patients with suspected stroke. NTAP pays 65% of the lesser of the technology's cost or the case's excess over the standard MS-DRG, effectively offsetting the per-facility subscription for Medicare stroke cases.
- · Viz LVO was the first AI software ever to receive a Medicare New Technology Add-on Payment (NTAP) — up to $1,040 per use in suspected-stroke patients — a reimbursement that helps hospitals offset the subscription cost.
- · Viz.ai publishes no prices: there is no /pricing page and every CTA is 'Request a demo' or 'Speak to an expert'; cost is quoted per facility, scaled by which of its 50+ FDA-cleared algorithms you license and the population you serve.
- · Viz.ai's stroke module cut time-to-specialist-notification from ~58.7 minutes (standard of care) to ~7.3 minutes — and at large stroke hubs reportedly lifted thrombectomy/surgery volume 50–60%, the downstream-revenue half of its ROI pitch.
Questions & answers
- What is Viz.ai's pricing model?
- Viz.ai is sales-led and does not publish list prices. The model is a quoted per-facility annual subscription, sold modularly by disease suite (Viz Neuro, Cardio, Vascular, Pulmonary and more) and scaled by how many of its 50+ FDA-cleared algorithms a hospital licenses and the size of the population it serves. There is no self-serve plan and no public rate card — every CTA is 'Request a demo' or 'Speak to an expert'.
- Does Viz.ai offer a free tier?
- No. There is no free tier and no public self-serve signup. Viz.ai is enterprise clinical software sold to hospitals and health systems via demo and a custom quote, deployed across PACS, EHR and on-call clinician mobile devices with a HIPAA review and BAA.
- How much does Viz.ai cost per hospital?
- Viz.ai does not disclose pricing publicly; cost is custom-quoted per facility based on which disease suites and algorithms are licensed and the population served. Third-party analyses of CMS filings have cited roughly $25,000 per year as an indicative example for the stroke module, varying by facility type (primary vs comprehensive stroke center) — treat that as third-party-reported, not official.
- How does Medicare NTAP affect Viz.ai's price?
- Viz LVO, the stroke-triage module, was the first AI software granted a Medicare New Technology Add-on Payment (NTAP) — up to $1,040 per eligible Medicare use. NTAP pays hospitals 65% of the lesser of the technology's cost or the amount a case exceeds the standard MS-DRG, on top of the DRG payment. For hospitals treating enough Medicare stroke patients, that per-use reimbursement effectively offsets the annual subscription.